Novacyt (FR:ALNOV) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Novacyt has achieved EU IVDR accreditation for its Yourgene® Cystic Fibrosis Base assay, marking it as one of the first CF tests to comply with the new rigorous standards. This accreditation assures the test’s quality and accuracy, enhancing its credibility among clinicians and patients across the EU and globally. With the potential for increased market momentum, especially in regions like Australia where reimbursement pathways have expanded, Novacyt’s position in the CF diagnostics market is set to strengthen.
For further insights into FR:ALNOV stock, check out TipRanks’ Stock Analysis page.
